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PHN who have insufﬁcient pain relief with standard analgesics
and do not tolerate or are contraindicated to tricyclic antide-
pressants. The model structure allowed for differences in costs,
utilities and transition probabilities between the initial 30-day
run-in period and maintenance therapy and also took account of
other medications that are added in alongside gabapentin/lido-
caine plaster and those received by patients discontinuing
gabapentin/lidocaine plaster. Most transition probabilities were
based on clinical trials identiﬁed through a systematic literature
review. Missing data, including resource utilization, were
obtained from a Delphi panel and cost data from ofﬁcial price
lists and tariffs. Utilities derived from a published study using
the Health Utilities Index were adjusted for age and were sup-
plemented and validated by the Delphi panel. RESULTS: The
total cost for lidocaine plaster was £958 per patient, compared
with £789 for gabapentin, although lidocaine plaster generated
0.292 quality-adjusted life-years (QALYs), compared with 0.248
for gabapentin. Lidocaine plaster therefore cost £3767 ($7370;
95% conﬁdence interval: dominant, £13,415) per QALY gained
relative to gabapentin. Probabilistic sensitivity analysis demon-
strated that we can be 98.7% conﬁdent that lidocaine plaster is
cost-effective relative to gabapentin at a £20,000/QALY thresh-
old and 65% conﬁdent at a £5000/QALY threshold. Scenario
analyses and extensive one-way sensitivity analyses on all para-
meters including the time horizon conﬁrmed the robustness of
the results. CONCLUSION: The lidocaine 5% plaster is a highly
cost-effective treatment for PHN in Scotland.
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OBJECTIVES: QuantiFERON-TB Gold assay (QFT-G) is a
recently approved blood test for detection of tuberculosis (TB)
infection. The advantages of tuberculin skin test (TST) are;
improved speciﬁcity, unaffected by prior BCG vaccination, and
single patient visit. The aim of this study was to examine the cost
effectiveness of using QFT-G as a screening test followed by the
standard treatment of TB infected patients after exposure in close
contacts in Japan. METHODS: We used a Markov model to
compare the cost and effectiveness of QFT-G alone, TST alone,
and TST followed by QFT-G using a hypothetical adult cohort
(20 years old) of close contact patients with sputum-smear-
positive TB patients. Main outcome measure was incremental
cost per Quality adjusted life year (QALY) gained during life-
time. In the model, costs and effectiveness of each screening test,
further chest X-ray examination, prophylaxis after identifying as
infected patients, and treatment for overt tuberculosis patients
who is not identiﬁed by screening or suffer from the disease even
after prophylaxis were considered and estimated with published
literatures. Both deterministic one-way and probabilistic sensi-
tivity analysis were performed. RESULTS: TST alone was the
most expensive and the least effective alternative. The mean
QALYs for QFT-G only strategy was slightly higher than that for
TST followed by QFT-G strategy (27.0565 vs. 27.0564). Total
costs from the societal perspective were higher on average for
the TST followed by QFT-G strategy ($120.9) than the QFT-G
alone strategy ($112.9). The incremental cost effectiveness ratio
for QFT-G alone strategy dominated. The results were robust in
deterministic one-way sensitivity analysis while the acceptability
curve showed that the QFT-G alone strategy has 99.6% chance
of being cost effective at $50,000/QALY gained threshold. CON-
CLUSION: QFT-G alone strategy is the least expensive and the
most effective in screening the TB infection after exposure in
close contacts in Japan.
RS2
INCREMENTAL COSTS ASSOCIATED WITH ANTIBIOTICS
PRESCRIBED FOR COMMUNITY ACQUIRED PNEUMONIA
Asche C1, Mucha L2, Lenhart G3, Seal B4
1University of Utah, Salt Lake City, UT, USA, 2Thomson Health care:
Medstat, Cambridge, MA, USA, 3Thomson Medstat, Cambridge, MA,
USA, 4Sanoﬁ-Aventis, Bridgewater, NJ, USA
OBJECTIVES: The purpose of this study was to estimate the
total and incremental costs associated with antibiotic treatments
for community acquired pneumonia (CAP). METHODS:
Persons over age 18 were identiﬁed in the Marketscan databases
July-December 2004. We identiﬁed CAP episodes for patients
with claims for ICD9 codes 481.XX–486.XX, plus the most fre-
quent antibiotics prescribed as initial treatment for an episode.
Logistic regression estimated a propensity score for each patient;
which was the predicted probability of using telithromycin.
Patients were then matched according to this probability. Then
exponential conditional means models (ECM) were speciﬁed,
controlling for variables that were still signiﬁcantly different
after the propensity score matching. These models allowed the
incremental costs to be estimated for treatment of telithromycin
relative to other antibiotics. RESULTS: The most common ini-
tial antibiotic treatments compared to telithromycin for CAP 
(n = 187 CAP episodes) were amoxicillin, azithromycin, clar-
ithromycin, levoﬂoxacin, moxiﬂoxacin, and a group of all other
antibiotics. The mean length of a CAP episode was from 11.5 to
16.5 days. Mean total expenditures among the episodes was
$897, with a range of $530 to $1175. Multivariate ECM models
were ﬁtted and showed signiﬁcant incremental cost reductions
per episode associated with telithromycin relative to: amoxicillin
(−$283, p = 0.002), azithromycin (−$686, p < 0.001), lev-
oﬂoxacin (−$411, p < 0.001), and moxiﬂoxacin (−$484, p <
0.001). The difference between telithromycin and clarithromycin
(−$52) was not signiﬁcant. CONCLUSION: The results of this
study show that the costs differed among episodes of CAP by the
initiating antibiotic. Use of propensity score matching and ECM
regression controlled for intra-episode differences, so the incre-
mental costs differences may be attributed to factors such as
length of episode. The costs of CAP can be substantial and it is
important to note that the initiating antibiotic may affect those
costs.
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OBJECTIVES: With increasing longevity among the elderly, it is
important to better understand the impact of chronic disease on
general health status. The objective of this study was to quan-
tify the health status burden of COPD for a nationally repre-
